Search Results - "Vergnenegre, A."

Multicentre phase II study of cisplatin–etoposide chemotherapy for advanced large-cell neuroendocrine lung carcinoma: the GFPC 0302 study by Le Treut, J., Sault, M.C., Lena, H., Souquet, P.J., Vergnenegre, A., Le Caer, H., Berard, H., Boffa, S., Monnet, I., Damotte, D., Chouaid, C.

“…The optimal treatment of large-cell neuroendocrine carcinoma (LCNEC) of the lung remains unclear. Here, our primary objective was to assess the efficacy of…”
Get full text

Clinical benefit of anti PD-1/PD-L1 plus chemotherapy versus chemotherapy alone in first-line treatment in advanced non-small cell lung cancer: A meta-analysis by Landre, T., Des Guetz, G., Vergnenegre, A., Chouaid, C.

Get full text

IMpower110: Interim overall survival (OS) analysis of a phase III study of atezolizumab (atezo) vs platinum-based chemotherapy (chemo) as first-line (1L) treatment (tx) in PD-L1–selected NSCLC by Spigel, D., de Marinis, F., Giaccone, G., Reinmuth, N., Vergnenegre, A., Barrios, C.H., Morise, M., Felip, E., Andric, Z.G., Geater, S., Özgüroğlu, M., Mocci, S., McCleland, M., Enquist, I., Komatsubara, K.M., Deng, Y., Kuriki, H., Wen, X., Jassem, J., Herbst, R.S.

Get full text

Patients with non-small-cell lung cancer harbouring a BRAF mutation: a multicentre study exploring clinical characteristics, management, and outcomes in a real-life setting: EXPLORE GFPC 02-14 by Auliac, J B, Bayle, S, Vergnenegre, A, Le Caer, H, Falchero, L, Gervais, R, Doubre, H, Vinas, F, Marin, B, Chouaid, C

“…Mutations in are rare oncogene mutations, found in 2% of non-small-cell lung cancers (nsclcs). Little information is available about the management of patients…”
Get full text

Management of malignant pleural mesothelioma: a French multicenter retrospective study (GFPC 0802 study) by Raynaud, C, Greillier, L, Mazieres, J, Monnet, I, Mastroianni, B, Robinet, G, Fraboulet, G, Dixmier, A, Berard, H, Lamy, R, Letreut, J, Lena, H, Oliviero, G, Botta, S, Vergnenegre, A, Borget, I, Chouaid, C

“…Malignant pleural mesothelioma (MPM) is a rare disease with poor prognosis in spite of significant improvement in survival, due to new chemotherapy regimens…”
Get full text

Randomized open-label non-comparative multicenter phase II trial of sequential erlotinib and docetaxel versus docetaxel alone in patients with non-small-cell lung cancer after failure of first-line chemotherapy: GFPC 10.02 study by Auliac, J.B, Chouaid, C, Greiller, L, Monnet, I, Le Caer, H, Falchero, L, Corre, R, Descourt, R, Bota, S, Berard, H, Schott, R, Bizieux, A, Fournel, P, Labrunie, A, Marin, B, Vergnenegre, A

“…Abstract Background Concomitant administration of erlotinib with standard chemotherapy does not appear to improve survival among patients with non-small-cell…”
Get full text

A multicentre phase II randomised trial of weekly docetaxel/gemcitabine followed by erlotinib on progression, vs the reverse sequence, in elderly patients with advanced non small-cell lung cancer selected with a comprehensive geriatric assessment (the GFPC 0504 study) by LeCaer, H, Barlesi, F, Corre, R, Jullian, H, Bota, S, Falchero, L, Vergnenegre, A, Dujon, C, Delhoume, J Y, Chouaid, C

“…Background: Elderly cancer patients form a heterogeneous population in which therapeutic decision-making is often difficult. The aim of this randomised phase…”
Get full text

A multicenter phase II randomized trial of gemcitabine followed by erlotinib at progression, versus the reverse sequence, in vulnerable elderly patients with advanced non small-cell lung cancer selected with a comprehensive geriatric assessment (the GFPC 0505 study) by LeCaer, H, Greillier, L, Corre, R, Jullian, H, Crequit, J, Falchero, L, Dujon, C, Berard, H, Vergnenegre, A, Chouaid, C

“…Abstract Background The aim of this randomized phase II trial was to evaluate the feasibility and activity of weekly gemcitabine (G) followed by erlotinib at…”
Get full text

Geriatric assessment contribution to treatment decision-making in thoracic oncology by Aliamus, V, Adam, C, Druet-Cabanac, M, Dantoine, T, Vergnenegre, A

“…Lung cancer is a frequently occurring disease among elderly people. The objective of this study was to search for a relationship between multimodal geriatric…”
Get more information

Impact of Continuing First-Line EGFR Tyrosine Kinase Inhibitor Therapy Beyond RECIST Disease Progression in Patients with Advanced EGFR-Mutated Non-Small-Cell Lung Cancer (NSCLC): Retrospective GFPC 04-13 Study by Auliac, J. B., Fournier, C., Audigier Valette, C., Perol, M., Bizieux, A., Vinas, F., Decroisette Phan van Ho, C., Bota Ouchlif, S., Corre, R., Le Garff, G., Fournel, P., Baize, N., Lamy, R., Vergnenegre, A., Arpin, D., Marin, B., Chouaid, C., Gervais, R.

“…Retrospective studies suggested a benefit of first-line tyrosine kinase inhibitor (TKI) treatment continuation after response evaluation in solid tumors…”
Get full text

Corrigendum to “Randomized open-label non-comparative multicenter phase II trial of sequential erlotinib and docetaxel versus docetaxel alone in patients with non-small-cell lung cancer after failure of first-line chemotherapy: GFPC 10.02 study” [Lung Cancer 85 (2014) 415–419] by Auliac, J.B, Chouaid, C, Greillier, L, Monnet, I, Le Caer, H, Falchero, L, Corre, R, Descourt, R, Bota, S, Berard, H, Schott, R, Bizieux, A, Fournel, P, Labrunie, A, Marin, B, Vergnenegre, A

Get full text

PCN109 Cost Effectiveness of First Line Tyrosine Kinase Inhibitor Treatment in Epidermal Growth Factor Receptor (EGFR) Mutated Advanced Non-Small Cell Lung Cancer (NSCLC) Patients: A Markov Model by Borget, I, Vergnenegre, A, Chouaid, C

Get full text

9056 POSTER Incidence and Management of Adverse Events (AEs) in Patients Receiving Different Types of Treatment for Non-small Cell Lung Cancer (NSCLC) Across Europe – EPICLIN-Lung Study by Currato, A, Cruciani, G, Vergnenegre, A, Blasco-Colmenares, E, Medina, J

Get full text

PCN9 From Indirect Evidence to Direct Evidence: A Real-World Example for the Value of Indirect Treatment Comparisons in Second-Line NSCLC Therapy by Schwander, B, Chouaid, C, Vergnenegre, A, Bischoff, H.G, Nuijten, M, Siebert, U, Walzer, S

Get full text

Tools for assessing healthcare delivery by Vergnenègre, A

“…Assessing the quality of care has become an essential part of the medical process. In France, the Professional Practice Evaluation requires a sound knowledge…”
Get more information

Simulation and Comparison of Progression-Free Survival (Pfs) Among Patients With Non-Squamous Non-Small Cell Lung Cancer (NSCLC) Receiving Sequential Therapy by Chouaid, C, Walzer, S, Lister, J, Gultyaev, D, Vergnenegre, A, de Marinis, F, Meng, J, de Castro, J, Crott, R, Kleman, M, Ngoh, C.A

Get full text

Clinical management patterns and treatment outcomes in patients with non-small cell lung cancer (NSCLC) across Europe: EPICLIN-Lung study by Carrato, A., Vergnenègre, A., Thomas, M., McBride, K., Medina, J., Cruciani, G.

“…Abstract Background: Throughout Europe, physicians face similar challenges in non-small cell lung cancer (NSCLC) management, but comprehensive international…”
Get full text

The costs of asthma in France and the economic implications of its level of control by Gadenne, S, Pribil, C, Chouaid, C, Vergnenegre, A, Detournay, B

“…The prevalence of asthma is increasing in France and the proportion of patients with poorly controlled or uncontrolled asthma remains significant. The economic…”
Get more information

9016 POSTER DISCUSSION Erlotinib Vs Chemotherapy (CT) in Advanced Non-Small-Cell Lung Cancer (NSCLC) Patients (p) With Epidermal Growth Factor Receptor (EGFR) Activating Mutations – the EURTAC Phase II Randomized Trial Interim Results by De Marinis, F, Rosell, R, Vergnenegre, A, Massuti, B, Felip, E, Gervais, R, Cardenal, F, Garcia-Gomez, R, Taron, M, Paz-Ares, L

Get full text

Cost-effectiveness analysis: a reader's guide by Vergnenègre, A

“…This article is devoted to the critical appraisal of cost-effectiveness analysis. The example chosen concerns the choice of first line chemotherapy for a…”
Get more information